Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Exposure to PFAS on Immune Responses to Td Vaccination
NCT06588530Phase 4Completed
- Sponsor
- Rutgers University
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tetanus toxoid in Tetanus and diphtheria, sponsored by Rutgers University. Primary endpoint: Change in Tetanus-diphtheria Specific IgG by PFNA Exposure Category at 30 days. Started Nov 2024; status: completed.
02
Drugs
tetanus toxoid
03
Conditions
Tetanusdiphtheria
Beyond the preview
Go deeper on NCT06588530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588530.